At baseline, 70.8% of patients in the intervention group were on anticoagulation versus 74.0% of controls. ... The prescription of [oral anticoagulants] may be a function of the healthcare system,” the editorialists wrote.
anticoagulants for at least six months after finishing at least three months of anticoagulant treatment. ... be considered for indefinite anticoagulation, regardless of their risk for recurrent VTE, the authors noted.
The study's results may assist clinicians in considering bleeding risk when choosing anticoagulant agents, the authors wrote. ... These findings indicate the potential benefits of a gastrointestinal bleeding risk assessment before initiating
2. DS. 2. -VASc risk score of 2 or higher on oral anticoagulants. ... and thereby reducing the potential for serious adverse drug events from [oral anticoagulants].”.
Which anticoagulation regimen will provide the greatest protection against thromboembolism during her pregnancy? ... Fixed-dose subcutaneous UFH may not provide adequate anticoagulation. LMWH can be used as an anticoagulant during pregnancy, but for
https://acpinternist.org/weekly/archives/2014/09/23/7.htm. The benefits and risks of 8 different anticoagulation strategies for patients with venous thromboembolism (VTE), including heparin and new oral anticoagulants, ... The benefits and risks of 8
https://acpinternist.org/weekly/archives/2019/07/16/2.htm. An accompanying editorial said that the current review supports a superior benefit profile of non-vitamin K oral anticoagulants (NOACs) in ... Non-vitamin K oral anticoagulants (NOACs) appear to
practical start-up and follow-up plans for patients taking new oral anticoagulants,. ... comparison of new anticoagulants and vitamin K antagonists in patients with AF and a malignancy.
group is, in our view, a strong argument in favour of not systematically treating calf DVT with anticoagulants,” the authors wrote. ... Avoidance of treating all calf DVTs with anticoagulants could be an important cost-saving strategy.”.
In patients with atrial fibrillation, the advantages of all 4 new oral anticoagulants over warfarin seem to outweigh the risks, a new meta-analysis found. ... This meta-analysis “support(s) the premise that compared with warfarin, new oral